Document |
Document Title |
WO/2005/000298A2 |
Provided are aminoaryl substituted 5-membered heterocycle-based p38 kinase, including p38alfa and p38beta. Pharmaceutical compositions containing the compounds are also provided. Method of use of the compounds and compositions are also p...
|
WO/2005/000231A2 |
This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
WO/2004/113310A1 |
The invention relates to a method for promoting wound healing, said method comprising administering to a mammal, including man, in need of such promotion an effective amount of an inhibitor of 11-ß-hydroxysteroid dehydrogenase type 1 wh...
|
WO/2004/111024A1 |
Disclosed are thiadiazoline derivatives represented by the general formula (I): (I) [wherein R1 represents a hydrogen atom or the like; R2 represents a hydrogen atom, -COR5 (wherein R5 represents a lower alkyl, etc.) or the like; R3 repr...
|
WO/2004/111023A1 |
Disclosed are thiadiazoline-1-oxide derivatives represented by the general formula (I): (I) (wherein R1, R2 and R4 represent hydrogen atoms, substituted or unsubstituted lower alkyls or the like; R3 represents a hydrogen atom or the like...
|
WO/2004/106280A1 |
A compound having a calcium-sensitive receptor antagonism; and a pharmaceutical composition comprising the compound. In particular, a calcium receptor antagonist; and a curative for osteoporosis. More specifically, a compound of the form...
|
WO/2004/103278A2 |
The present invention relates a series of compounds of Formula I, wherein R1, R2, R3, and B are as defined in the specification. The compounds are useful for the inhibition of HIV integrase and for the treatment of AIDS or ARC by adminis...
|
WO/2004/103980A1 |
The present invention relates to compounds with the formula (I) and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on th...
|
WO/2004/103366A1 |
The present invention relates to substituted diphenyl heterocycle compounds according to structural formula (I) where the B ring is an aromatic ring that includes from one to four heteroatomes, and pharmaceutical compositions thereof tha...
|
WO/2004/099165A2 |
The present invention relates to substituted diphenyl heterocycle compounds according to formula (I), (II), (III) and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the us...
|
WO2004087053A9 |
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising the formula (I): wherein Q is selected from the group consisting of CO, SO, SO2, or C=NR9; and R1, R...
|
WO/2004/092147A1 |
An M-stage kinesin Eg5 inhibitor which contains as an active ingredient either a thiadiazoline derivative represented by the general formula (I): [wherein R1 represents hydrogen, etc.; R2 represents hydrogen, -C(=W)R6 (wherein W represen...
|
WO/2004/092116A1 |
Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical...
|
WO/2004/089885A1 |
The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
|
WO/2004/087684A1 |
The present invention relates to novel benzo[1,2,5]oxadiazoles and benzo[1,2,5]thiadiazoles of formula (I) wherein X is O or S, R1 is 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2-18F-ethylamino)- thiazol-2-yl or a group of formula (a) wher...
|
WO/2004/085411A1 |
This invention relates to novel heterocyclic compounds of formula (I) wherein R1- R4, X1 and X2 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficien...
|
WO/2004/076432A1 |
The invention relates to new 2,2,3,3-tetramethylcyclopropane carboxamide derivative compounds, pharmaceutical compositions thereof and uses thereof for treating psychotic disorders, neurodegenerative diseases, epilepsy and pain.
|
WO/2004/075864A2 |
Compounds of Formula (I) wherein R1, R2, R3, and R4 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor fun...
|
WO/2004/076420A1 |
A compound represented by the following formula (I): (I) [wherein X1 represents oxygen, etc.; X2 represents oxygen, etc.; R1 represents an alkylsulfonyl or another group on the ring A; R2 represents, e.g., C3-7 cyclic alkyl optionally su...
|
WO/2004/067498A2 |
The invention relates to compounds of general formula (I), where n = a whole number from 1 to 7, A is selected from one or several groups X, Y and/or Z, X = C1-2 alkylene, optionally substituted by one or more C1-12 alkyl, C3-7 cycloalky...
|
WO/2004/063181A1 |
The present invention provides compositions and their use in the treatment of inflammatory diseases caused by T-cell proliferation such as sepsis, inflammatory bowel diseases, autoimmune encephalomyelitis, or lupus. The compositions comp...
|
WO/2004/063179A1 |
According to the present invention there is provided a compounds of formula (I): and pharmaceutically acceptable salts thereof.
|
WO/2004/062601A2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...
|
WO/2004/062664A1 |
The present invention relates to novel phosphate isosteres. The invention relates to compounds having a sulfhydantoin or a reverse sulfhydantoin moiety, uses thereof, and related methods. The present invention relates to compounds of for...
|
WO/2004/060305A2 |
Novel compounds and methods of using those compounds for the treatment of oncological conditions are provided. In a preferred embodiment, modulation of the activation states of abl or bcr-abl &agr -kinase proteins comprises the step of c...
|
WO/2004/061084A2 |
New methods for the rational identification of molecules capable of interacting with specific naturally occurring proteins are provided, in order to yield new pharmacologically important compounds and treatment modalities. Broadly, the m...
|
WO/2004/060306A2 |
Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kina...
|
WO/2004/058911A2 |
The invention relates to the improvement of organic electroluminescent devices. Said devices are characterised in that the emitting layer (EML) consists of a mixture of two substances, one having hole-conductive characteristics and the o...
|
WO/2004/058174A2 |
This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in p...
|
WO/2004/056735A1 |
Compounds of formula (I), wherein: A1 is, for example, a bond or a C1-C6alkylene bridge; A2 is, for example, a bond or C1-C6alkylene; A3 is, for example, C1-C6alkylene; W is, for example, O or S; T is, for example, a bond, O, NH, NR7, S,...
|
WO/2004/056789A1 |
This invention provides substituted Phenyl-(2-[1,3,4]thiadiazol-2-ylphenyl)-amine and (2-[1,3,4]Oxadiazol-2-yl-phenyl)phenyl-amine compounds which act as inhibitors of MAPKIERK Kinase ('MEK') enzymes and pharmaceutical compositions and...
|
WO/2004/050646A1 |
The invention concerns compounds of the formula (I) or pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4, and R5 have any of the meanings defined in the description.Processes for the manufacture of compounds of formula (I)...
|
WO/2004/050613A2 |
This invention provides 2-substituted-propenamide derivatives and their compositions for the treament of hepatitis B virus and/or hepatitis D virus.
|
WO/2004/046095A1 |
The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antivira...
|
WO/2004/046125A1 |
The present invention relates to a novel 1,2,4-thiadiazole compound represented by the formula (1): wherein, R?1¿ represents C3-C7 alkynyl that may be substituted with halogen atom; R?2¿ represents C3-C8 cycloalkyl which may be substit...
|
WO/2004/041264A1 |
Compounds of formula (I): Formula (I) wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described.
|
WO/2004/041799A1 |
The invention concerns compounds of the formula (I) or pharmaceutically acceptable salts thereof (A chemical formula should be inserted here - please see paper copy enclosed herewith) wherein R1, R2, R3, R4, R5, and R6 have any of the me...
|
WO/2004/041798A1 |
1,2,4−Thiadiazole compounds represented by the general formula (1) have excellent control activities against injurious arthropods: (1) wherein R1 is C3−7 alkynyl which may be halogenated&semi R2 is halogeno, C1−4 alkyl, C1−4 halo...
|
WO/2004/037800A1 |
The present invention relates to novel benzyloxy derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
|
WO/2004/035556A1 |
The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders ...
|
WO/2004/033440A1 |
Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl,...
|
WO/2004/033652A2 |
Improved competitive inhibitors of FAAH employ an &agr -keto heterocyclic pharmacophore and a binding subunit having a ?-unsaturation. The &agr -keto heterocyclic pharmacophore and a binding subunit are attached to one another, preferabl...
|
WO/2004/033452A1 |
A thiadiazole compound represented by the formula (A): (A) wherein R1 represents C1-7 alkyl, C3-7 alkenyl, C3-7 alkynyl, etc.; and R2 represents C1-4 alkyl substituted by an optionally substituted heterocyclic group (provided that the he...
|
WO/2004/033419A1 |
Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and me...
|
WO/2004/031137A1 |
Compounds of formula (I) inhibit the processing of APP by gamma-secretase, and hence are useful in treatment of Alzheimer's disease.
|
WO/2004/024686A1 |
It is pointed out that the existing crosslinking agents and condensing agents having been employed in biological adhesives and in treating medical devices such as cardiac valves, which are non-natural products synthesized artificially, a...
|
WO/2004/022775A1 |
A method for identifying antibacterial agents comprises depleting bacteria of a strain comprising a luxAB construct of Ca2+, incubating the Ca2+ depleted bacteria with an agent the antibacterial effect of which shall be determined, recor...
|
WO/2004/020445A2 |
Compounds of formula (I) wherein Ao is a bond or a C1-C6alkylene bridge; A1, A2 and A3 are a C1-C6alkylene bridge; D is CH or N; W is, for example, O, S, SO, S02, -C(=O)-O- or -O-C(=O)-; T is a bond or, for example, O, NH, S, SO or SR2; ...
|
WO2004000789A9 |
The present invention is directed to compounds, compositions, and use of compounds the structural Formula (I).
|
WO2003028642A9 |
The invention relates to methods for preventing and treating disseminating cancers. Inhibition metastases of a primary tumor to a liver tissue is carried out by directly contacting a liver tissue with Taurolidine.
|